Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC increased its stake in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 6.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 598,229 shares of the biotechnology company’s stock after purchasing an additional 38,412 shares during the quarter. Renaissance Technologies LLC owned about 4.10% of Anika Therapeutics worth $15,153,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of ANIK. BNP Paribas Financial Markets lifted its holdings in Anika Therapeutics by 34.2% in the fourth quarter. BNP Paribas Financial Markets now owns 19,023 shares of the biotechnology company’s stock worth $431,000 after purchasing an additional 4,852 shares during the period. Trexquant Investment LP lifted its holdings in Anika Therapeutics by 15.4% in the 4th quarter. Trexquant Investment LP now owns 58,463 shares of the biotechnology company’s stock valued at $1,325,000 after acquiring an additional 7,811 shares during the last quarter. Quest Partners LLC acquired a new stake in Anika Therapeutics in the 4th quarter valued at about $156,000. Franklin Resources Inc. lifted its holdings in Anika Therapeutics by 16.9% in the 4th quarter. Franklin Resources Inc. now owns 133,611 shares of the biotechnology company’s stock valued at $3,028,000 after acquiring an additional 19,276 shares during the last quarter. Finally, Invenomic Capital Management LP lifted its holdings in Anika Therapeutics by 124.6% in the 4th quarter. Invenomic Capital Management LP now owns 210,332 shares of the biotechnology company’s stock valued at $4,766,000 after acquiring an additional 116,679 shares during the last quarter. Institutional investors and hedge funds own 91.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Barrington Research reissued an “outperform” rating and issued a $37.00 price target on shares of Anika Therapeutics in a report on Friday, August 9th. Stephens reissued an “equal weight” rating and issued a $24.00 price target on shares of Anika Therapeutics in a report on Wednesday, May 29th.

Anika Therapeutics Trading Up 0.6 %

ANIK stock opened at $25.50 on Friday. Anika Therapeutics, Inc. has a one year low of $17.44 and a one year high of $29.11. The firm has a market capitalization of $371.97 million, a PE ratio of -4.86 and a beta of 0.83. The firm has a 50-day moving average of $26.02 and a two-hundred day moving average of $25.89.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.24). Anika Therapeutics had a negative net margin of 44.45% and a positive return on equity of 0.94%. The firm had revenue of $41.92 million for the quarter, compared to analysts’ expectations of $39.90 million. During the same period in the prior year, the company posted ($0.06) earnings per share. On average, equities research analysts anticipate that Anika Therapeutics, Inc. will post -0.1 earnings per share for the current year.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.